AstraZeneca and Targacept announce first top-line Phase III results for TC-5214 as an adjunct treatment in patients with major depressive disorder
8 November 2011 | By AstraZeneca
Top-line results announced...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
8 November 2011 | By AstraZeneca
Top-line results announced...
26 October 2011 | By AstraZeneca
US FDA has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months...
21 October 2011 | By AstraZeneca
AstraZeneca will present key results from health economics sub-studies...
18 October 2011 | By AstraZeneca
ceftazidime/avibactam (CAZ-AVI) will enter phase III trials...
10 October 2011 | By AstraZeneca
AstraZeneca announced a $200 million investment in a new manufacturing facility...
5 October 2011 | By Astrazeneca
AstraZeneca enters into a settlement agreement with Accord Healthcare, Inc. & Intas Pharmaceuticals Ltd...
4 October 2011 | By AstraZeneca
Report published on BRILIQUE (ticagrelor)...
26 September 2011 | By AstraZeneca
AstraZeneca announced that FASLODEX™ (fulvestrant) has received regulatory approval...
23 September 2011 | By AstraZeneca
KOMBOGLYZE™ receives a positive opinion from CHMP...
2 September 2011 | By AstraZeneca
SATURN measures the impact of rosuvastatin and atorvastatin on the progression of atherosclerosis in high risk patients...
1 September 2011 | By AstraZeneca
Transaction worth $1.8 billion in cash was completed on 31 August 2011...
In this eLN supplement: eLNs - An essential productivity tool - but which one to use?; Using an eLN to create GMP compliant records for drug substance manufacture; Implementation of an electronic lab notebook system at VIB; eLN roundtable...
31 August 2011 | By Geoff Holdgate, AstraZeneca
Recently, there has been renewed interest in using thermodynamic and kinetic data, alongside empirical rules (particularly focused upon cLogP and molecular weight) and guiding metrics such as ligand efficiency and lipophilic ligand efficiency developed for fragments, leads and drugs in order to facilitate the design of compounds with a greater…
2 August 2011 | By AstraZeneca
AstraZeneca announced that AXANUM has received positive agreement for approval...
20 July 2011 | By AstraZeneca
The US FDA has approved BRILINTA (ticagrelor) tablets...